CMTA News
Archived Headlines
- US IPO Week Ahead: A Huntsman spinoff, a rare bone disease biotech, and Snap's lock-up 07/28/17
- US IPO Weekly Recap: Investors remain discerning amid increased activity 07/21/17
- Bone disease biotech Clementia Pharmaceuticals sets terms for $100 million IPO 07/21/17
- Bone disease biotech Clementia Pharmaceuticals files for a $115 million IPO 06/30/17
Two biotech IPOs were just acquired for $1+ billion each
Biotechs got a shot in the arm on Monday, with $1+ billion acquisitions of 2015 and 2017 IPOs. Gene therapy biotech Spark Therapeutics spiked 120% on Monday after announcing that it would be acquired by Roche for about $4.8 billion....read more
US IPO Week Ahead: No IPOs during the final week of the August lull
There are no IPOs scheduled to price in the week ahead. While nothing is currently on the calendar, expect that to change after Labor Day, when recent filers start launching. With just five IPOs this month (six, including the one SPAC), August 2017 will be...read more
US IPO Weekly Recap: Two IPOs start off the annual August lull
Two IPOs raised a combined $574 million this past week and notched modest gains. Pigments supplier Venator Materials raised $454 million and ultra-rare bone disease biotech Clementia Pharmaceuticals raised $120 million. July 2017 was the ...read more
Ultra-rare bone disease biotech Clementia Pharmaceuticals prices upsized IPO at $15 high end
Clementia Pharmaceuticals, a clinical-stage biotech focused on treating ultra-rare bone diseases, raised $120 million by offering 8 million shares at $15, the high end of the range of $13 to $15. The company had previously planned to offer 7.15 million shares....read more